Dec. 2, 2024—Microbiologics announced the acquisition of SensID, a manufacturer of reference materials and quality controls for molecular diagnostics, with a focus on oncology and precision medicine. The combination of Microbiologics’ infectious disease diagnostic solutions and SensID’s molecular oncology expertise will ensure that the companies are well-positioned to lead in the diagnostic quality control market, according to a Microbiologics press statement.
“We are excited to welcome SensID into the Microbiologics team,” said Kristen Knox, CEO of Microbiologics. “This partnership isn’t just about expanding our capabilities; it’s about bringing together two organizations who are deeply passionate about advancing the future of diagnostics. At the heart of everything we do is a commitment to improving the lives of patients and health care professionals around the world. By combining our expertise in infectious disease and oncology diagnostics, we can make an even greater impact.”
Based in St. Cloud, Minn., Microbiologics offers a broad collection of third-party in vitro diagnostic controls for simple, reliable QC testing of traditional and molecular infectious disease diagnostics. SensID will continue operations at its headquarters in Rostock, Germany.